TRiAD - Xpert MTB/XDR Publications

Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin

18 May 2022

By Samantha Pillay

Can the GeneXpert MTB/XDR deliver on the promise of expanded, near-patient tuberculosis drug-susceptibility testing?

25 Feb 2022

By Kogie Naidoo,

Xpert MTB/XDR for rapid detection of drug-resistant tuberculosis beyond rifampicin

07 Oct 2021

By Nomonde R Mvelase

Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study

07 Oct 2021

By Adam Penn-Nicholson

Analytical performance of the Xpert MTB/XDR® assay for tuberculosis and expanded resistance detection

10 Apr 2021

By Sophia B Georghiou

Xpert MTB/XDR: a 10-Color Reflex Assay Suitable for Point-of-Care Settings To Detect Isoniazid, Fluoroquinolone, and Second-Line-Injectable-Drug Resistance Directly from Mycobacterium tuberculosis-Positive Sputum

22 Nov 2020

By Yuan Cao